Meridia Risk Management Program Sufficiently Addresses Safety Issues, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency denies Public Citizen petition to remove Abbott’s weight loss drug Meridia (sibutramine) from the market.
You may also be interested in...
Public Citizen Re-Petitions FDA To Withdraw Obesity Drug Meridia
Public Citizen has renewed its call for FDA to ban Abbott's obesity drug Meridia (sibutramine) following the release of preliminary results of a 10,000 patient study that showed the drug had a slightly higher rate of cardiovascular events
Public Citizen Re-Petitions FDA To Withdraw Obesity Drug Meridia
Public Citizen has renewed its call for FDA to ban Abbott's obesity drug Meridia (sibutramine) following the release of preliminary results of a 10,000 patient study that showed the drug had a slightly higher rate of cardiovascular events
Meridia Pediatric Adverse Events Will Get Continued Monitoring
FDA notes that only one pediatric adverse case report was recorded and additional surveillance is necessary for a more meaningful analysis.